Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Insurance Marketplaces Won’t ‘Move The Needle’ Near-Term For Pharma Economics – An Interview With Booz & Co.

Executive Summary

Jan. 1, 2014, the date insurance coverage expansion begins, is a key marker in the implementation of the Affordable Care Act, but experts, including Booz & Co. partners Elizabeth Powers and Greg Rotz say it isn’t likely to have a big near-term impact on drug manufacturers. Initial enrollment into health insurance exchanges and expanded Medicaid programs is expected to be limited, benefit plan designs are still unknown, and many uncertainties remain.

You may also be interested in...



Biopharma Sizes Up The Affordable Care Act: Buyer’s Remorse Or Winner’s Curse?

Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.

Deals Of The Week Ponders The ACA

In a slow week for pharma deals, standouts included GSK’s wrap up with MorphoSys for a mid-stage rheumatoid arthritis drug, Pfizer’s deal to gain access to novel kinds of antibody drug-conjugates through platform company CytomX, and the first microbiome deal between a big pharma (Janssen) and a start-up, Second Genome.

Wall Street’s Take On Health Care Exchanges

Health care exchanges for expanding insurance coverage as part of the Affordable Care Act will open in time to meet the law’s January 1 deadline, but their “robustness” and ease of use, at least initially, may be questionable, a panel of experts tells Wall Street.

Related Content

Topics

UsernamePublicRestriction

Register

PS055203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel